{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 40,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a 2x2 grid of metrics to frame the market opportunity, followed by specific target population and success threshold data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/15",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "list",
      "text": "Target population: ~50K AXL+ addressable 2L+ patients/year in the U.S., based on AXL positivity rate of ~35%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85943240-18b4-426d-90b9-66b3697bb40e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "list",
      "text": "Internal success threshold: 2L+ ORR of ~15% - 20% (approvability bar based on precedent); 20%+ (commercially relevant) following BA3011 monotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99f643a8-0762-4a47-b546-8d7dfb9b787c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.33,
        "x": 0.37,
        "y": 0.185
      },
      "kind": "metric",
      "text": "~200K newly diagnosed patients / year (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31a92e30-dd12-4333-845f-e14859a405d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.33,
        "x": 0.03,
        "y": 0.185
      },
      "kind": "metric",
      "text": ">540K people in the U.S. living with lung cancer",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b93b7ea9-b3b0-4629-bc40-fe575f2f6d92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.33,
        "x": 0.03,
        "y": 0.44
      },
      "kind": "metric",
      "text": "2L+ despite advances in 1L care, majority of patients progress",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8ca96d4-6ebf-4aba-b258-ee87e0c266c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.33,
        "x": 0.37,
        "y": 0.44
      },
      "kind": "metric",
      "text": "~75% non-squamous cell represents majority of patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0ce0d7b-846b-4fa4-adb4-ec253a16e057",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.11,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1L, first line; 2L+, second line or greater; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOC, standard of care",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "457f1342-d30e-4b32-8f70-676f26c02986",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Potential market opportunity in metastatic NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c25b97f-5606-48d3-856b-0de0e864129d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 15,
      "from": 9,
      "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck presents the potential market opportunity for BioAtla's CABs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 1,
      "objective": "What are the key results and milestones for BioAtla's CABs?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}